NeoGenomics Inc. announced that new data utilizing its RaDaR® 1.0 circulating tumor DNA (ctDNA) assay will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. The company will showcase findings from the CLEVER study and the SURVIVE HERoes Phase III trial, both of which evaluate RaDaR-based ctDNA testing for molecular residual disease (MRD) detection and recurrence risk in early breast cancer. The CLEVER study examines five-year outcomes and ctDNA findings in patients with high-risk breast cancer, reporting that positive ctDNA often precedes clinical recurrence by several months. The results will be presented by investigators from the University of Pennsylvania on December 11, 2025. The SURVIVE HERoes Phase III trial investigates therapeutic intervention at the point of molecular relapse in HER2-positive or HER2-low early breast cancer, before radiographic evidence of disease appears. Investigators from University Hospital Ulm will present these results on December 12, 2025. Additionally, the ongoing SURVIVE Phase III case-control trial will provide an update on using RaDaR liquid biopsy for earlier recurrence detection and potential overall survival improvement, with status updates also scheduled for December 12, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210950923) on December 10, 2025, and is solely responsible for the information contained therein.
Comments